WARNING: CONTRAINDICATED IN HEART FAILURE PATIENTS Cilostazol tablets are contraindicated in patients with heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure [see Contraindications (4)].
WARNING: CONTRAINDICATED IN HEART FAILURE PATIENTS See full prescribing information for complete boxed warning. Cilostazol tablets are contraindicated in patients with heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with the pharmacologic effect have caused decreased survival compared to placebo patients with class III-IV heart failure.
(4)
Use: Labeled indications
- Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol tablets are a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance (1)
Contraindications
4 CONTRAINDICATIONS Cilostazol tablets are contraindicated in patients with: Heart failure of any severity: Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure. Hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema) Heart failure of any severity (4) Hypersensitivity to cilostazol or any components of cilostazol tablets (4)
US FDA labelDosing: Adult
- The recommended dosage of cilostazol tablets is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner (2.1)
- Reduce the dose to 50 mg twice daily when coadministered with CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, and diltiazem, or CYP2C19 inhibitors such as ticlopidine, fluconazole, and omeprazole (2.2)
2.1 Recommended
2.1 Recommended dosage The recommended dosage of cilostazol tablets is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner. Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.
If symptoms are unimproved after 3 months, discontinue cilostazol tablets.
2.2 Dose Reduction with CYP3A4 and CYP2C19 Inhibitors
2.2 Dose Reduction with CYP3A4 and CYP2C19 Inhibitors Reduce dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, erythromycin, and diltiazem) or inhibitors of CYP2C19 (e.g., ticlopidine, fluconazole, and omeprazole) [see Drug Interactions (7.1)].
Dosing: Altered kidney function
8.7 Renal Impairment No dose adjustment is required in patients with renal impairment. Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%) [see Clinical Pharmacology (12.3)].
Renal Impairment: The total pharmacologic activity of cilostazol and its metabolites was similar in subjects with mild to moderate renal impairment and in healthy subjects. Severe renal impairment increases metabolite levels and alters protein binding of the parent. The expected pharmacologic activity, however, based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites, appeared little changed.
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment No dose adjustment is required in patients with mild hepatic impairment. Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of cilostazol tablets in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects (n = 2,274) in clinical studies of cilostazol tablets, 56 percent were 65 years old and over, while 16 percent were 75 years old and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be excluded.
Pharmacokinetic studies have not disclosed any age-related effects on the absorption, distribution, metabolism, and elimination of cilostazol and its metabolites.
Dosage forms
Philippines
- Tablet: 50 mg, 100 mg
- Extended-release tablet: 100 mg, 200 mg
- Controlled-release tablet: 100 mg, 200 mg
- Sustained-release capsule: 100 mg
Registered products in the Philippines
85 products registered with the Food and Drug Administration (FDA) Philippines list Cilostazol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products85
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AggravanCilostazol | 50 mg TabletFoil Strip x 10's (Box of 30's) | Rx | PT DEXA MEDICAIndonesia | Glorious Dexa Mandaya, Inc | DRP-6007 | Jan 20, 2029 | |
CatazolCilostazol | 100 mg TabletFoil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DRP-8570 | Apr 20, 2030 | |
Ciloheme 100Cilostazol | 100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation.Importer: Ambica International Corporation | DRP-14373 | Aug 30, 2028 | |
Ciloheme 50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation.Importer: Ambica International Corporation | DRP-14374 | Aug 30, 2028 | |
CiloproCilostazol | 100 mg TabletAlu/Alu Strip Foil x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Transcend Phils., Inc. | DRP-7523 | Mar 11, 2030 | |
Cilosol 100Cilostazol | 100 mg TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) xx 10's (Box of 100's) | Rx | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY48784 | Jun 23, 2028 | |
Cilosol 50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Unison Laboratories Co., Ltd.Thailand | JustRight Healthcare Inc. | DR-XY47385 | Sep 15, 2031 | |
CilostadinCilostazol | 100 mg TabletBlister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Importer: Medchoice CNS Pharma Corporation | DRP-5650-05 | Jul 9, 2027 | |
CilostadinCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Medchoice CNS Pharma CorporationImporter: Ambica International Corporation | DRP-4555-04 | Dec 9, 2027 | |
Cilostal-100Cilostazol | 100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation.Importer: Ambica International Corporation | DRP-14744 | Dec 20, 2028 | |
Cilostal-50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-19093 | Oct 27, 2031 | |
Cilostan CrCilostazol | 100 mg Controlled Release TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Korea United Pharm. Inc.Korea | One Pharma Marketing Inc. | DR-XY48745 | Jun 5, 2028 | |
Cilostan CRCilostazol | 200 mg Controlled-Release TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | Rx | Korea United Pharm. Inc.Republic of Korea | One Pharma Marketing Inc. | DR-XY44984 | Jan 19, 2032 | |
Cilozallen-B50Cilostazol | 50 mg TabletAlu/Clear Pvc Blister Pack Of 10'S (Box of 100's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-17966 | Apr 30, 2031 | |
CiloziaCilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc. | DRP-16282 | Jan 27, 2030 | |
Cilozol-100Cilostazol | 100 mg tabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-8518 | Oct 24, 2029 | |
Cilozol-50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-8519 | Oct 24, 2029 | |
CirozitCilostazol | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 10's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-14655 | Nov 17, 2028 | |
ClaudenCilostazol | 100 mg TabletFoil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Aldril Pharmaceuticals, Inc.Trader: Total Care Pharma Inc. | DRP-15052 | Apr 16, 2030 | |
ClaudenCilostazol | 50 mg TabletAluminum Foil Strip x 10's Box of 30's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DR-XY43330 | Apr 1, 2029 | |
ClaudenCilostazol | 50 mg TabletAluminum Foil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: TotalCare Pharma Inc. | DRP-16126 | Apr 1, 2029 | |
Claudisaph-GE 100Cilostazol | 100 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17967 | Apr 16, 2031 | |
ClazolCilostazol | 100 mg TabletAluminum Foil Strip x 10s (Box of 50's) | Rx | Macleods Pharmaceuticals Limited (Unit II)India | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-7541 | Nov 28, 2031 | |
ClazolCilostazol | 50 mg Tablet | Rx | Macleods Pharmaceuticals Limited (Unit II) | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-7191 | Nov 27, 2026 | |
CloscizolCilostazol | 100 mg TabletBlister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5650-07 | Jul 9, 2027 | |
CloscizolCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4555-07 | Dec 9, 2027 | |
Clostelo 100Cilostazol | 100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Cooper Pharma LimitedIndia | Bewell Nutraceuticals Corp.Importer: Ambica International Corporation | DRP-14373-02 | Aug 30, 2028 | |
Clostelo 100Cilostazol | 100 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Cadila Pharmaceuticals LimitedIndia | Bewell Nutraceuticals Corp.Importer: Ambica International Corporation | DRP-5650-08 | Jul 9, 2027 | |
Clostelo 50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Cooper Pharma LimitedIndia | Bewell Nutraceuticals Corp.Importer: Ambica International Corporation | DRP-14374-03 | Aug 30, 2028 | |
Clostelo 50Cilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s | Rx | Cadila Pharmaceuticals LimitedIndia | Bewell Nutraceuticals Corp.Importer: Ambica International Corporation | DRP-4555-08 | Dec 9, 2027 | |
ClotecCilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | Rx | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-14045 | Jun 8, 2028 | |
DisolvCilostazol | 100 mg TabletAlu-Alu Blister pack x 10's (Box of 30's) | Rx | Cooper Pharma LImitedIndia | Preventia Healthcare Inc,Importer: Suhitas Pharmaceuticals Inc. | DRP-5350 | Jun 20, 2027 | |
DisolvCilostazol | 50 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-5441 | Aug 15, 2027 | |
Gociflex 50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-5441-02 | Aug 15, 2027 | |
Hematozol 100Cilostazol | 100 mg TabletBlister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-5650-06 | Jul 9, 2027 | |
Hematozol 50Cilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-4555-09 | Dec 9, 2027 | |
NoneCilostazol | 100 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) | Rx | Novagen Healthcare Private LimitedIndia | Medethix, Inc. | DRP-17527 | Sep 9, 2031 | |
NoneCilostazol | 100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-14373-01 | Aug 30, 2028 | |
NoneCilostazol | 100 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Cooper Pharma LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14373-03 | Aug 30, 2028 | |
NoneCilostazol | 100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-14744-02 | Dec 20, 2028 | |
NoneCilostazol | 100 mg TabletBlister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Actimed, Inc.Importer: Ambica International Corporation | DRP-5650-02 | Jul 9, 2027 | |
NoneCilostazol | 100 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Korea Otsuka Pharmaceutical Co., Ltd.Republic of Korea | Philusa CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc. | DRP-6289-01 | May 22, 2029 | |
NoneCilostazol | 100 mg TabletFoil Strip x 10's Box of 30's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-8726 | Mar 11, 2030 | |
NoneCilostazol | 200 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) | Rx | Novagen Healthcare Private LimitedIndia | Medethix, Inc. | DRP-17526 | Sep 9, 2031 | |
NoneCilostazol | 50 mg TabletAlu/Foil Strip x 10's Box of 30's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY46165 | Nov 21, 2027 | |
NoneCilostazol | 50 mg TabletAlu/Foil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DRP-13708 | Nov 21, 2027 | |
NoneCilostazol | 50 mg TabletAlu/Foil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Dr. Zen's Research, Inc. | DRP-13708-01 | Nov 21, 2027 | |
NoneCilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-14374-01 | Aug 30, 2028 | |
NoneCilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-14374-02 | Aug 30, 2028 | |
NoneCilostazol | 50 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14374-05 | Aug 30, 2028 | |
NoneCilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Reta DrugImporter: Ambica International Corporation | DRP-14374-06 | Aug 30, 2028 | |
NoneCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s | Rx | Cadila Pharmaceuticals LimitedIndia | Actimed, Inc.Importer: Ambica International Corporation | DRP-4555-03 | Dec 9, 2027 | |
NoneCilostazol | 50 mg TabletBlister Pack x 10's Box of 100's | Rx | Korea Otsuka Pharmaceutical Co., Ltd.Republic of Korea | Philusa CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc. | DRP-6290-01 | May 22, 2029 | |
Ostaz-50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | 4Care Lifescience Pvt. Ltd.India | Aglobal Care, IncImporter: Aglobal Care, Inc. | DR-XY14952 | Feb 21, 2029 | |
Ostaz-50Cilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | 4Care Lifescience Pvt. Ltd.India | Aglobal Care, IncImporter: Aglobal Care, Inc. | DRP-14951 | Feb 21, 2029 | |
Pencil 100Cilostazol | 100 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Cadila Pharmaceuticals LimitedIndia | Kaufmann Pharma Inc.Importer: Ambica International Corporation | DRP-5650 | Jul 9, 2032 | |
Pencil 50Cilostazol | 50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Cadila Pharmaceuticals LimitedIndia | Kaufmann Pharma Inc.Importer: Ambica International Corporation | DRP-4555 | Dec 9, 2027 | |
PlatecilCilostazol | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Towa Pharmaceutical Co., Ltd.Japan | Trader: Crisdy-Na Drug Corporation | DR-XY39304 | Apr 13, 2028 | |
PlatecilCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Towa Pharmaceutical Co., Ltd.Japan | Trader: Crisdy-Na Drug Corporation | DR-XY39305 | Apr 13, 2028 | |
PlazolCilostazol | 50 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Standard Chem. & Pharm Co., Ltd. Standard Chem. & Pharm Co., Ltd.Taiwan | PHIL PHARMAWEALTH, INC. | DR-XY42648 | Sep 18, 2028 | |
PletaalCilostazol | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's); Blister Pack x 15's | Rx | Korea Otsuka Pharmaceutical Co., Ltd.Republic of Korea | Importer: OTSUKA (PHILIPPINES) PHARMACEUTICAL, INC. | DRP-6289 | May 22, 2029 | |
PletaalCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's); Alu/PVC Blister Pack x 15's | Rx | Korea Otsuka Pharmaceutical Co. Ltd.Korea | Importer: OTSUKA (PHILIPPINES) PHARMACEUTICAL, INC. | DRP-6290 | May 22, 2029 | |
Pletaal SRCilostazol | 100 mg Sustained Release CapsuleAlu/Alu Blister Foil x 10's (Box of 60's) | Rx | Korea Otsuka Pharmaceutical Co., Ltd.Korea | Otsuka (Philippines) Pharmaceutical, Inc. | DRP-12858 | Apr 4, 2030 | |
PletarCilostazol | 100 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14744-01 | Dec 20, 2028 | |
PletaxolCilostazol | 100 mg TabletFoil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7495 | Apr 16, 2030 | |
PletaxolCilostazol | 50 mg TabletAlu/Strip Foil x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7494 | Dec 18, 2029 | |
PletazCilostazol | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Cooper Pharma LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14374-04 | Aug 30, 2028 | |
PlezolCilostazol | 50 mg TabletAlu/Alu Foil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-7522 | Jul 15, 2029 | |
Tazol 100Cilostazol | 100 mg TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 30's); Alu/Clear PVC/PVDC Blister Pack x 10's (Box of 100's); Alu/Clear PVC/PVDC Blister Pack x 10's (Box of 10's as Physician Sample) | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-7305 | Feb 26, 2031 | |
Tazollen-B100Cilostazol | 100 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-17109 | Sep 30, 2031 | |
ThromboranCilostazol | 100 mg TabletAlu-Alu Blister pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-5350-01 | Jun 20, 2027 | |
ThromboranCilostazol | 50 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-5441-01 | Aug 15, 2027 | |
ThromzolCilostazol | 100 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Cadila Pharmaceuticals LimitedIndia | Bell-Kenz Pharma Inc.Importer: Ambica International Corporation | DRP-5650-04 | Jul 9, 2032 | |
ThromzolCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-4555-06 | Dec 9, 2027 | |
Thromzol 100Cilostazol | 100 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) | Rx | Novagen Healthcare Private LimitedIndia | Bell-Kenz Pharma Inc.Importer: I.E. Medica, Inc. | DRP-17528-01 | Jan 23, 2031 | |
TrombocilCilostazol | 100 mg TabletAlu Foil Strip x 10's (Box of 100s) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-9890 | Dec 12, 2027 | |
TrombocilCilostazol | 50 mg TabletAlu Foil Strip x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-9889 | Nov 5, 2027 | |
UnbrandedCilostazol | 50 mg TabletAlu/Foil Strip x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-10188 | May 26, 2029 | |
VaxolCilostazol | 100 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Cadila Pharmaceuticals LimitedIndia | The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation | DRP-5650-03 | Jul 9, 2032 | |
VaxolCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation | DRP-4555-05 | Dec 9, 2027 | |
ZatsolCilostazol | 100 mg TabletBlister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5650-01 | Jul 9, 2027 | |
ZatsolCilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s | Rx | Cadila Pharmaceuticals LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4555-02 | Dec 9, 2027 | |
ZoloscaCilostazol | 200 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) | Rx | Novagen Healthcare Private LimitedIndia | Medethix, Inc. | DRP-17525 | Sep 9, 2031 | |
(no brand name)Cilostazol | 100 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) | Rx | Novagen Healthcare Private LimitedIndia | I.E Medica, Inc. | DRP-17528 | Jan 23, 2031 | |
(no brand name)Cilostazol | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Cadila Pharmaceuticals LimitedIndia | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-4555-01 | Dec 9, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Cilostazol Tablets, USP are available containing 50 mg or 100 mg of cilostazol USP. The 50 mg tablets are white to off-white, round, flat bevel edged tablets debossed with ‘CI’ on one side and ‘50’ on other side. The 100 mg tablets are white to off-white, round, flat bevel edged tablets debossed with ‘CI’ on one side and ‘100’ on other side. Tablets: 50 mg and 100 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease (5.2)
- Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum (5.1)
- Risks of thrombocytopenia or leukopenia progressing to agranulocytosis- monitor platelets and white blood cell counts (5.3)
- Avoid use in patients with hemostatic disorders or active pathologic bleeding (5.4)
5.1 Tachycardia
5.1 Tachycardia Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.
5.2 Left Ventricular Outflow Tract Obstruction
5.2 Left Ventricular Outflow Tract Obstruction Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum. Monitor patients for the development of a new systolic murmur or cardiac symptoms after starting cilostazol.
5.3 Hematologic Adverse Reactions
5.3 Hematologic Adverse Reactions Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol tablets were not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol tablets. Monitor platelets and white blood cell counts periodically.
5.4 Hemostatic Disorders or Active Pathologic Bleeding
5.4 Hemostatic Disorders or Active Pathologic Bleeding Cilostazol tablets inhibit platelet aggregation in a reversible manner. Cilostazol tablets have not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol tablets in these patients.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol tablets. Reduce cilostazol tablets dose (2.2, 7.1) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4: Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol tablets.
Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. Inhibitors of CYP2C19: Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol tablets active metabolites.
Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Based on in vitro studies, the primary isoenzymes involved in cilostazol’s metabolism are CYP3A4 and, to a lesser extent, CYP2C19.
Drug Interactions: Cilostazol does not appear to inhibit CYP3A4 .
Strong Inhibitors of CYP3A4: A priming dose of ketoconazole 400 mg (a strong inhibitor of CYP3A4), was given one day prior to coadministration of single doses of ketoconazole 400 mg and cilostazol 100 mg.
Other strong inhibitors of CYP3A4, such as itraconazole, voriconazole, clarithromycin, ritonavir, saquinavir, and nefazodone would be expected to have a similar effect [see Dosage and Administration (2.2) , Drug Interactions (7.1) ] .
Moderate Inhibitors of CYP3A4: Erythromycin and Other Macrolide Antibiotics : Erythromycin is a moderately strong inhibitor of CYP3A4.
Inhibitors of CYP2C19: Omeprazole: Coadministration of omeprazole did not significantly affect the metabolism of cilostazol, but the systemic exposure to 3,4-dehydro-cilostazol was increased by 69%, probably the result of omeprazole’s potent inhibition of CYP2C19 [ see Dosage and Administration (2.2) ] .
7 DRUG INTERACTIONS Strong and moderate CYP3A4 and CYP2C19 inhibitors : Increase exposure to cilostazol tablets.
Reduce cilostazol tablets dose ( 2.2 , 7.1 ) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4: Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol tablets.
Adverse reactions
- The following adverse reactions are discussed in greater detail in other sections of the labeling: Patients with Heart Failure [see Boxed Warning] Tachycardia [see Warnings and Precautions (5.1)] Left Ventricular Outflow Tract Obstruction [see Warnings and Precautions (5.2)] Hematologic Adverse Reactions [see Warnings and Precautions (5.3)] Hemostatic Disorders or Active Pathologic Bleeding [see Warnings and Precautions 5.4)] Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily cilostazol tablets (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol tablets and 134 days for patients on placebo.
The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with cilostazol tablets was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol tablets (all doses) versus 0.1% for placebo.
The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol tablets 50 or 100 mg twice daily, are shown in Table 1. Table 1: Most Common Adverse Reactions in Patients on Cilostazol Tablets 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (≥ 2%) in the 100 mg Twice Daily Group than on Placebo) Adverse Reactions Placebo (N = 973) Cilostazol Tablets 50 mg twice daily (N = 303) Cilostazol Tablets 100 mg twice daily (N = 998) Headache 14% 27% 34% Diarrhea 7% 12% 19% Abnormal stools 4% 12% 15% Palpitation 1% 5% 10% Dizziness 6% 9% 10% Pharyngitis 7% 7% 10% Infection 8% 14% 10% Peripheral edema 4% 9% 7% Rhinitis 5% 12% 7% Dyspepsia 4% 6% 6% Abdominal pain 3% 4% 5% Tachycardia 1% 4% 4% Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with cilostazol tablets 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below.
Body as a Whole: fever, generalized edema, malaise Cardiovascular: atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia Digestive: anorexia, melena Hematologic and Lymphatic: anemia Metabolic and Nutritional: increased creatinine, hyperuricemia Nervous: insomnia Respiratory: epistaxis Skin and Appendages: urticaria Special Senses: conjunctivitis, retinal hemorrhage, tinnitus Urogenital: urinary frequency
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cilostazol tablets. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and Lymphatic System Disorders: Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency Cardiac Disorders: Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g., complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris. Gastrointestinal Disorders: Gastrointestinal hemorrhage, vomiting, flatulence, nausea General Disorders and Administration Site Conditions: Pain, chest pain, hot flushes Hepatobiliary Disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Immune System Disorders: Anaphylaxis, angioedema, and hypersensitivity Investigations: Blood glucose increased, blood uric acid increased, increase in BUN (blood urea increased), blood pressure increase Nervous System Disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma and subdural hematoma Renal and Urinary Disorders: Hematuria Respiratory, Thoracic and Mediastinal Disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and Subcutaneous Tissue Disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa), rash Vascular Disorders: Subacute stent thrombosis, hypertension.
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reactions | Placebo (N = 973) | Cilostazol Tablets 50 mg twice daily (N = 303) | Cilostazol Tablets 100 mg twice daily (N = 998) |
| Headache | 14% | 27% | 34% |
| Diarrhea | 7% | 12% | 19% |
| Abnormal stools | 4% | 12% | 15% |
| Palpitation | 1% | 5% | 10% |
| Dizziness | 6% | 9% | 10% |
| Pharyngitis | 7% | 7% | 10% |
| Infection | 8% | 14% | 10% |
| Peripheral edema | 4% | 9% | 7% |
| Rhinitis | 5% | 12% | 7% |
| Dyspepsia | 4% | 6% | 6% |
| Abdominal pain | 3% | 4% | 5% |
| Tachycardia | 1% | 4% | 4% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Teratogenic Effects: Pregnancy Category C: Cilostazol tablets have been shown to be teratogenic in rats at doses that are greater than 5-times the human MRHD on a body surface area basis. There are no adequate and well-controlled studies in pregnant women. In a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular septal, aortic arch and subclavian artery abnormalities, renal pelvic dilation, 14th rib, and retarded ossification).
At this dose, systemic exposure to unbound cilostazol in nonpregnant rats was about 5 times the exposure in humans given the MRHD. Increased incidences of ventricular septal defect and retarded ossification were also noted at 150 mg/kg/day (5 times the MRHD on a systemic exposure basis). In a rabbit developmental toxicity study, an increased incidence of retardation of ossification of the sternum was seen at doses as low as 150 mg/kg/day.
In nonpregnant rabbits given 150 mg/kg/day, exposure to unbound cilostazol was considerably lower than that seen in humans given the MRHD, and exposure to 3,4-dehydro-cilostazol was barely detectable. When cilostazol was administered to rats during late pregnancy and lactation, an increased incidence of stillborn and decreased birth weights of offspring was seen at doses of 150 mg/kg/day (5 times the MRHD on a systemic exposure basis).
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 Nursing Mothers Transfer of cilostazol into milk has been reported in rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from cilostazol tablets, discontinue nursing or discontinue cilostazol tablets.
Mechanism of action
12.1 Mechanism of Action Cilostazol tablets and several of its metabolites inhibit phosphodiesterase III activity and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively. Cilostazol tablets reversibly inhibit platelet aggregation induced by a variety of stimuli, including thrombin, ADP, collagen, arachidonic acid, epinephrine, and shear stress.
Cardiovascular Effects: Cilostazol affects both vascular beds and cardiovascular function. It produces heterogeneous dilation of vascular beds, with greater dilation in femoral beds than in vertebral, carotid or superior mesenteric arteries. Renal arteries were not responsive to the effects of cilostazol. In dogs or cynomolgus monkeys, cilostazol increased heart rate, myocardial contractile force, and coronary blood flow as well as ventricular automaticity, as would be expected for a PDE III inhibitor.
Left ventricular contractility was increased at doses required to inhibit platelet aggregation. A-V conduction was accelerated. In humans, heart rate increased in a dose-proportional manner by a mean of 5.1 and 7.4 beats per minute in patients treated with 50 and 100 mg twice daily, respectively.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Cilostazol's effects on platelet aggregation were evaluated in both healthy subjects and in patients with stable symptoms of cerebral thrombosis, cerebral embolism, transient ischemic attack, or cerebral arteriosclerosis over a range of doses from 50 mg every day to 100 mg three times a day. Cilostazol significantly inhibited platelet aggregation in a dose-dependent manner.
The effects were observed as early as 3 hours post-dose and lasted up to 12 hours following a single dose. Following chronic administration and withdrawal of cilostazol, the effects on platelet aggregation began to subside 48 hours after withdrawal and returned to baseline by 96 hours with no rebound effect. A cilostazol dosage of 100 mg twice daily consistently inhibited platelet aggregation induced with arachidonic acid, collagen and adenosine diphosphate (ADP).
Bleeding time was not affected by cilostazol administration. Effects on circulating plasma lipids have been examined in patients taking cilostazol tablets. After 12 weeks, as compared to placebo, cilostazol tablets 100 mg twice daily produced a reduction in triglycerides of 29.3 mg/dL (15%) and an increase in HDL-cholesterol of 4.0 mg/dL (≅ 10%).
Drug Interactions: Aspirin: Short-term (less than or equal to 4 days) coadministration of aspirin with cilostazol tablets increased the inhibition of ADP-induced ex vivo platelet aggregation by 22% to 37% when compared to either aspirin or cilostazol tablets alone. Short-term (less than or equal to 4 days) coadministration of aspirin with cilostazol tablets increased the inhibition of arachidonic acid-induced ex vivo platelet aggregation by 20% compared to cilostazol tablets alone and by 48% compared to aspirin alone.
However, short-term coadministration of aspirin with cilostazol tablets had no clinically significant impact on PT, aPTT, or bleeding time compared to aspirin alone. Effects of long-term coadministration in the general population are unknown. In eight randomized, placebo-controlled, double-blind clinical trials, aspirin was coadministered with cilostazol to 201 patients.
The most frequent doses and mean durations of aspirin therapy were 75 to 81 mg daily for 137 days (107 patients) and 325 mg daily for 54 days (85 patients). There was no apparent increase in frequency of hemorrhagic adverse effects in patients taking cilostazol and aspirin compared to patients taking placebo and equivalent doses of aspirin.
Warfarin: Cilostazol did not inhibit the pharmacologic effects (PT, aPTT, bleeding time, or platelet aggregation) of R- and S-warfarin after a single 25 mg dose of warfarin. The effect of concomitant multiple dosing of warfarin and cilostazol tablets on the pharmacodynamics of both drugs is unknown.
Pharmacokinetics
Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine.
Metabolism: Cilostazol is eliminated predominantly by metabolism and subsequent urinary excretion of metabolites.
Elimination: The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%).
No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydrocilostazol.
About 30% of the dose was excreted in urine as 4´-trans-hydroxy-cilostazol.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Cilostazol tablets are absorbed after oral administration. A high fat meal increases absorption, with an approximately 90% increase in C max and a 25% increase in AUC. Absolute bioavailability is not known. Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine.
Two metabolites are active, with one metabolite appearing to account for at least 50% of the pharmacologic (PDE III inhibition) activity after administration of cilostazol tablets. Pharmacokinetics are approximately dose proportional. Cilostazol and its active metabolites have apparent elimination half-lives of about 11-13 hours.
Cilostazol and its active metabolites accumulate about 2-fold with chronic administration and reach steady state blood levels within a few days. The pharmacokinetics of cilostazol and its two major active metabolites were similar in healthy subjects and patients with intermittent claudication due to peripheral arterial disease (PAD).
Figure 1 shows the mean plasma concentration-time profile at steady state after multiple dosing of cilostazol tablets 100 mg twice daily. Figure 1: Mean Plasma Concentration-time Profile at Steady State after Multiple Dosing of Cilostazol Tablets 100 mg Twice Daily Distribution: Cilostazol is 95 to 98% protein bound, predominantly to albumin.
The binding for 3,4-dehydro-cilostazol is 97.4% and for 4´-trans-hydroxy-cilostazol is 66%. Mild hepatic impairment did not affect protein binding. The free fraction of cilostazol was 27% higher in subjects with renal impairment than in healthy volunteers. The displacement of cilostazol from plasma proteins by erythromycin, quinidine, warfarin, and omeprazole was not clinically significant.
Metabolism: Cilostazol is eliminated predominantly by metabolism and subsequent urinary excretion of metabolites. Based on in vitro studies, the primary isoenzymes involved in cilostazol’s metabolism are CYP3A4 and, to a lesser extent, CYP2C19. The enzyme responsible for metabolism of 3,4-dehydro-cilostazol, the most active of the metabolites, is unknown.
Following oral administration of 100 mg radiolabeled cilostazol, 56% of the total analytes in plasma was cilostazol, 15% was 3,4-dehydro-cilostazol (4 to 7 times as active as cilostazol), and 4% was 4´-trans-hydroxy-cilostazol (20% as active as cilostazol). Elimination: The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%).
No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydrocilostazol. About 30% of the dose was excreted in urine as 4´-trans-hydroxy-cilostazol. The remainder was excreted as other metabolites, none of which exceeded 5%. There was no evidence of induction of hepatic microenzymes.
Special Populations: Age and Gender: The total and unbound oral clearances, adjusted for body weight, of cilostazol and its metabolites were not significantly different with respect to age (50 to 80 years) or gender. Smokers: Population pharmacokinetic analysis suggests that smoking decreased cilostazol exposure by about 20%.
Hepatic Impairment: The pharmacokinetics of cilostazol and its metabolites were similar in subjects with mild hepatic disease as compared to healthy subjects. Patients with moderate or severe hepatic impairment have not been studied. Renal Impairment: The total pharmacologic activity of cilostazol and its metabolites was similar in subjects with mild to moderate renal impairment and in healthy subjects.
Severe renal impairment increases metabolite levels and alters protein binding of the parent. The expected pharmacologic activity, however, based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites, appeared little changed. Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
Drug Interactions: Cilostazol does not appear to inhibit CYP3A4. Warfarin: Cilostazol did not inhibit the metabolism of R- and S-warfarin after a single 25 mg dose of warfarin. Clopidogrel: Multiple doses of clopidogrel do not significantly increase steady state plasma concentrations of cilostazol. Strong Inhibitors of CYP3A4: A priming dose of ketoconazole 400 mg (a strong inhibitor of CYP3A4), was given one day prior to coadministration of single doses of ketoconazole 400 mg and cilostazol 100 mg.
This regimen increased cilostazol C max by 94% and AUC by 117%. Other strong inhibitors of CYP3A4, such as itraconazole, voriconazole, clarithromycin, ritonavir, saquinavir, and nefazodone would be expected to have a similar effect [see Dosage and Administration (2.2), Drug Interactions (7.1)]. Moderate Inhibitors of CYP3A4: Erythromycin and Other Macrolide Antibiotics: Erythromycin is a moderately strong inhibitor of CYP3A4.
Coadministration of erythromycin 500 mg every 8h with a single dose of cilostazol 100 mg increased cilostazol C max by 47% and AUC by 73%. Inhibition of cilostazol metabolism by erythromycin increased the AUC of 4´-trans-hydroxycilostazol by 141% [see Dosage and Administration (2.2)]. Diltiazem: Diltiazem 180 mg decreased the clearance of cilostazol by ~30%.
Cilostazol C max increased ~30% and AUC increased ~40% [see Dosage and Administration (2.2)]. Grapefruit Juice: Grapefruit juice increased the C max of cilostazol by ~50%, but had no effect on AUC. Inhibitors of CYP2C19: Omeprazole: Coadministration of omeprazole did not significantly affect the metabolism of cilostazol, but the systemic exposure to 3,4-dehydro-cilostazol was increased by 69%, probably the result of omeprazole’s potent inhibition of CYP2C19 [see Dosage and Administration (2.2)].
Quinidine: Concomitant administration of quinidine with a single dose of cilostazol 100 mg did not alter cilostazol pharmacokinetics. Lovastatin: The concomitant administration of lovastatin with cilostazol decreases cilostazol C ss, max and AUC τ by 15%. There is also a decrease, although nonsignificant, in cilostazol metabolite concentrations.
Coadministration of cilostazol with lovastatin increases lovastatin and ß-hydroxylovastatin AUC approximately 70% and is not expected to be clinically significant. Figure 1
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Cilostazol 50 mg Tablet | ₱6.50–₱11.55Reference ₱7.72 | per tablet | DPRI procurement range |
| Cilostazol 100 mg Tablet | ₱12.50–₱16.00Reference ₱12.85 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Cilostazol |
| PNF listing | Oral: 50 mg and 100 mg tablet |
| PNF listing | Oral: 50 mg (20% w/w), 0.25 g sachet powder for oral |
| PNF listing | Oral: use |
| PNF listing | Oral: 100 mg (20% w/w), 0.5 g sachet powder for oral use |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. CILOSTAZOL · Aurobindo Pharma Limited [US FDA-approved label, version 1, October 1, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c841eed-a98f-43c3-baaf-bf5502207a69
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .